Deferoxamine for the Prevention of Acute Kidney Injury
去铁胺预防急性肾损伤
基本信息
- 批准号:10670112
- 负责人:
- 金额:$ 73.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAcuteAcute Renal Failure with Renal Papillary NecrosisAdultAffinityAnimal ModelAnimalsAtrial FibrillationAttenuatedBindingBloodBostonCD14 geneCardiacCardiac Surgery proceduresCardiac VolumeCardiopulmonary BypassCell surfaceCessation of lifeChronicChronic Kidney FailureCirculationClinicalComplexComplicationConduct Clinical TrialsControlled EnvironmentCreatinineCritical IllnessDataDeferoxamineDeliriumDevelopmentDouble-Blind MethodEnrollmentExcretory functionExposure toFecesFerritinFlow CytometryFunctional disorderHemeHemoglobinHemolysisHospitalsHourHumanHypotensionIncidenceInflammationInflammatoryInfrastructureInfusion proceduresInjuryInjury to KidneyInterleukin-6Intravenous infusion proceduresInvestigationIronIron Chelating AgentsIron ChelationIron OverloadIsoprostanesKidneyLCN2 geneLeft Ventricular Ejection FractionMeasuresMechanical ventilationMediatingMyocardial InfarctionNormal salineOperative Surgical ProceduresOrganOutcomeOutputOxidative StressPathogenesisPatientsPeroxidasesPhasePhenotypePhysiologicalPlacebosPlasmaPlayPostoperative PeriodPre-Clinical ModelPreventionProductionProspective, cohort studyPublic HealthRandomizedRandomized, Controlled TrialsRenal Replacement TherapyRiskRoleSepsisSerumSeveritiesSurgeonTNF geneTestingTherapeuticTranscriptTransferrinTubular formationUrinecytokineexperiencehigh riskimprovedinflammatory markerinjury preventioninnovationinsightiron metabolismmonocytemortality riskmyocardial injurynephrotoxicitynew therapeutic targetnext generationnovelorgan injuryoxidative damageparticipant enrollmentperipheral bloodpharmacologicprecision medicinepreventprimary endpointprophylacticresearch studysecondary endpointtranscriptometranscriptome sequencingtranslational studyurinary
项目摘要
PROJECT SUMMARY
Acute kidney injury (AKI) is a common and often devastating complication of cardiac surgery, critical
illness, and other clinical settings. No pharmacologic therapy reliably prevents or treats AKI. Abundant data
from both animal models and humans indicates that iron plays a key role in the pathogenesis of AKI,
particularly in the setting of cardiac surgery. We propose a phase II, double-blind, randomized controlled trial
to test whether administration of the iron chelating agent, deferoxamine (DFO), prevents AKI following cardiac
surgery. We will enroll 300 adult patients at high risk of AKI following cardiac surgery at three major academic
medical centers in Boston. Patients will be randomly assigned, in a 1:1 fashion (n=150/group), to receive DFO
(30 mg/kg) or an equal volume of normal saline. DFO (or normal saline) will be administered as a continuous
24-hour intravenous infusion beginning immediately prior to surgery.
In Aim 1 we will test the effects of DFO compared to placebo on the incidence of postoperative AKI
(primary endpoint). AKI will be defined by changes in serum creatinine and urine output, according to the
KDIGO criteria. As secondary endpoints, we will assess longitudinal changes in urinary tubular injury markers,
NGAL and KIM-1. We will also test the effects of DFO on the incidence of the following common and
biologically plausible extrarenal postoperative endpoints: myocardial infarction, atrial fibrillation, delirium,
prolonged mechanical ventilation, and sepsis.
In Aim 2 we will tests the effects of DFO compared to placebo on longitudinal measures of circulating
iron and oxidative stress, and the inflammatory phenotype of monocytes. Serum iron parameters will include
catalytic iron – a toxic, non-physiologic iron species – as well as transferrin saturation and ferritin. Plasma
markers of oxidative stress will include F(2)-isoprostane and myeloperoxidase. We will also assess the effect
of DFO versus placebo on monocyte (CD14+) expression of IL-6, TNFα, and other markers of inflammation
using flow cytometry. In exploratory analyses, we will use next-generation RNA sequencing (RNA-Seq) to
assess the effect of DFO on the transcriptome of monocytes, which will facilitate discovery of novel transcripts
influenced by DFO. We will also determine the extent to which the effect of DFO on renal and extrarenal acute
organ injury (assessed in Aim 1) varies depending on the preoperative expression of key parameters
measured in Aim 2.
In aggregate, the studies proposed here will test a novel and promising therapeutic strategy for AKI
prevention. These studies have strong potential to improve clinical outcomes in patients at risk for AKI.
Further, the translational studies proposed here will yield important scientific insights into the role of iron
metabolism in the pathophysiology of AKI.
项目摘要
急性肾损伤(阿基)是心脏手术的常见且通常是毁灭性的并发症,
疾病和其他临床环境。没有药物治疗可以可靠地预防或治疗阿基。丰富的数据
表明铁在阿基的发病机制中起关键作用,
特别是在心脏手术的环境中。我们建议进行一项II期、双盲、随机对照试验
为了测试施用铁螯合剂去铁胺(DFO)是否预防心脏病后阿基,
手术我们将在三个主要学术机构招募300名心脏手术后阿基高风险的成年患者,
波士顿的医疗中心患者将以1:1的方式随机分配(n=150/组),接受DFO治疗
(30 mg/kg)或等体积的生理盐水。DFO(或生理盐水)将作为连续给药
24-在手术前立即开始静脉输注1小时。
在目标1中,我们将测试DFO与安慰剂相比对术后阿基发生率的影响
(主要终点)。阿基将根据血清肌酐和尿量的变化定义,
KDIGO标准。作为次要终点,我们将评估肾小管损伤标志物的纵向变化,
NGAL和KIM-1。我们还将测试DFO对以下常见疾病发生率的影响
生物学上合理的肾外术后终点:心肌梗死、房颤、谵妄,
长时间机械通气和败血症
在目标2中,我们将测试DFO与安慰剂相比对循环系统纵向测量的影响。
铁和氧化应激,以及单核细胞的炎症表型。血清铁参数将包括
催化铁-一种有毒的非生理铁物质-以及转铁蛋白饱和和铁蛋白。血浆
氧化应激的标志物包括F(2)-异前列烷和髓过氧化物酶。我们也会评估
DFO与安慰剂对单核细胞(CD 14+)表达IL-6、TNFα和其他炎症标志物的影响
使用流式细胞术。在探索性分析中,我们将使用下一代RNA测序(RNA-Seq),
评估DFO对单核细胞转录组的影响,这将有助于发现新的转录本
受DFO影响。我们还将确定DFO对肾和肾外急性炎症的影响程度,
器官损伤(在目标1中评估)取决于关键参数的术前表达
在目标2中测量。
总的来说,本文提出的研究将测试一种新颖且有前途的阿基治疗策略。
预防这些研究具有很大的潜力来改善有阿基风险的患者的临床结果。
此外,这里提出的转化研究将对铁的作用产生重要的科学见解
代谢在阿基的病理生理学中的作用。
项目成果
期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sarcopenia, adiposity and large discordance between cystatin C and creatinine-based estimated glomerular filtration rate in patients with cancer.
癌症患者的肌肉减少症、肥胖以及胱抑素 C 和基于肌酐的估计肾小球滤过率之间的巨大不一致。
- DOI:10.1002/jcsm.13469
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Hanna,PaulE;Ouyang,Tianqi;Tahir,Ismail;Katz-Agranov,Nurit;Wang,Qiyu;Mantz,Lea;Strohbehn,Ian;Moreno,Daiana;Harden,Destiny;Dinulos,JamesE;Cosar,Duru;Seethapathy,Harish;Gainor,JustinF;Shah,SachinJ;Gupta,Shruti;Leaf,DavidE;
- 通讯作者:
Platelet Factor 4 Antibodies and Severe AKI.
- DOI:10.34067/kid.0000000000000287
- 发表时间:2023-12-01
- 期刊:
- 影响因子:0
- 作者:Thomas C;Ali R;Park I;Kim H;Short S;Kaunfer S;Durai L;Yilmam OA;Shenoy T;Battinelli EM;Al-Samkari H;Leaf DE
- 通讯作者:Leaf DE
Intraoperative Oxygen Practices in Cardiac Surgery: A National Survey.
- DOI:10.1053/j.jvca.2022.01.019
- 发表时间:2022-08
- 期刊:
- 影响因子:2.8
- 作者:
- 通讯作者:
Histopathologic Correlates of Kidney Function: Insights From Nephrectomy Specimens.
肾功能的组织病理学相关性:来自肾切除标本的见解。
- DOI:10.1053/j.ajkd.2020.08.015
- 发表时间:2021
- 期刊:
- 影响因子:0
- 作者:Li,Ping;Gupta,Shruti;Mothi,SurajS;Rennke,HelmutG;Leaf,DavidE;Waikar,SushrutS;McMahon,GearoidM
- 通讯作者:McMahon,GearoidM
Tocilizumab in COVID-19: some clarity amid controversy.
- DOI:10.1016/s0140-6736(21)00712-1
- 发表时间:2021-05-01
- 期刊:
- 影响因子:0
- 作者:Gupta S;Leaf DE
- 通讯作者:Leaf DE
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Evan Leaf其他文献
David Evan Leaf的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Evan Leaf', 18)}}的其他基金
Hepcidin-Ferroportin-Iron Axis in Cardiac Surgery-associated Acute Kidney Injury
心脏手术相关急性肾损伤中的铁调素-铁转运蛋白-铁轴
- 批准号:
10659183 - 财政年份:2022
- 资助金额:
$ 73.48万 - 项目类别:
Hepcidin-Ferroportin-Iron Axis in Cardiac Surgery-associated Acute Kidney Injury
心脏手术相关急性肾损伤中的铁调素-铁转运蛋白-铁轴
- 批准号:
10444522 - 财政年份:2022
- 资助金额:
$ 73.48万 - 项目类别:
Deferoxamine for the Prevention of Acute Kidney Injury
去铁胺预防急性肾损伤
- 批准号:
10442625 - 财政年份:2020
- 资助金额:
$ 73.48万 - 项目类别:
Deferoxamine for the Prevention of Acute Kidney Injury
去铁胺预防急性肾损伤
- 批准号:
10249293 - 财政年份:2020
- 资助金额:
$ 73.48万 - 项目类别:
Deferoxamine for the Prevention of Acute Kidney Injury
去铁胺预防急性肾损伤
- 批准号:
10034169 - 财政年份:2020
- 资助金额:
$ 73.48万 - 项目类别:
Precision Medicine Approach to Vitamin D3 Administration in Critical Illness
危重疾病维生素 D3 给药的精准医学方法
- 批准号:
10444999 - 财政年份:2019
- 资助金额:
$ 73.48万 - 项目类别:
Precision Medicine Approach to Vitamin D3 Administration in Critical Illness
危重疾病维生素 D3 给药的精准医学方法
- 批准号:
9916797 - 财政年份:2019
- 资助金额:
$ 73.48万 - 项目类别:
Precision Medicine Approach to Vitamin D3 Administration in Critical Illness
危重疾病维生素 D3 给药的精准医学方法
- 批准号:
10217234 - 财政年份:2019
- 资助金额:
$ 73.48万 - 项目类别:
Dysregulated Mineral Metabolism in Acute Kidney Injury
急性肾损伤时矿物质代谢失调
- 批准号:
8702918 - 财政年份:2013
- 资助金额:
$ 73.48万 - 项目类别:
Dysregulated Mineral Metabolism in Acute Kidney Injury
急性肾损伤时矿物质代谢失调
- 批准号:
8588596 - 财政年份:2013
- 资助金额:
$ 73.48万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 73.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 73.48万 - 项目类别:
Operating Grants














{{item.name}}会员




